In this article, we will discuss Olaparib (Clinical Trials Experience-7). So, let’s get started.
There were 8 (4%) patients with adverse reactions leading to death, two were attributed to acute leukemia, and one each was attributed to COPD, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, and suture rupture. The median exposure to Olaparib capsules in these patients was 5.2 months.